Form 4: VolitionRx Chief Scientific Officer Reports Routine Stock Transaction for Tax Withholding

VolitionRx Ltd.'s Chief Scientific Officer, Jacob Vincent Micallef, reported a routine disposition of 21,526 common shares to cover tax obligations related to the settlement of restricted stock units.

Summary

• Jacob Vincent Micallef, Chief Scientific Officer of VolitionRx Ltd. (VNRX), filed a Form 4 with the SEC.
• The filing details a transaction on June 1, 2025, where 21,526 shares of common stock were disposed of.
• These shares were retained by VolitionRx to satisfy tax withholding obligations upon the settlement of 47,837 restricted stock units (RSUs) awarded to Mr. Micallef.
• The RSUs were granted in lieu of cash compensation, and no shares were sold by the reporting person or VolitionRx for personal gain in this transaction.
• Following this transaction, Mr. Micallef directly beneficially owns 404,507 shares of common stock.
• Additionally, he indirectly beneficially owns 55,000 shares through his spouse and 38,113 shares through Borlaug Limited, where he serves as a controlling director with voting and dispositive control.

Sentiment

Score: 5

Explanation: The document reports a routine insider transaction for tax withholding on RSU vesting, which is a neutral event and does not indicate positive or negative sentiment about the company's performance or outlook.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically related to tax withholding upon the vesting of restricted stock units. Such transactions are common across all industries for executives receiving equity compensation and do not typically reflect specific industry trends or competitive positioning.

Stakeholder Impact

• The transaction is a routine administrative event related to executive compensation and is unlikely to have a direct material impact on shareholders, employees, customers, suppliers, or creditors beyond standard compensation practices.

Key Dates

Keywords

VolitionRx, VNRX, SEC Form 4, Insider Transaction, Restricted Stock Units, Tax Withholding, Beneficial Ownership, Jacob Vincent Micallef, Chief Scientific Officer